Better Therapeutics Inc

NASDAQ:BTTX   3:59:51 PM EDT
1.83
+0.04 (+2.24%)
Products

Better Therapeutics Submits De Novo Request To U.S. FDA For BT-001 Investigational Prescription Digital Therapy For Type 2 Diabetes

Published: 09/22/2022 12:13 GMT
Better Therapeutics Inc (BTTX) - Better Therapeutics Submits De Novo Request to U.S. FDA for Bt-001 Investigational Prescription Digital Therapy for Type 2 Diabetes.
Better Therapeutics Inc - Submission Follows Completion of First-in-class Trial Demonstrating Improvements in A1c Reduction With Investigational Therapy Targeting Causes of Type 2 Diabetes.
Better Therapeutics Inc - If Authorized by FDA, Bt-001 Would Be First Validated, Prescription Solution for Delivering Cbt to T2d Patients at Scale.
Better Therapeutics Inc - Bt-001 Results Achieved Were Sustainable and Improved Between Day 90 and Day 180 of Trial.